Wei Wang1,2, Xinjie Wang1, Mehrdad Rajaei1, Ji Youn Youn1, Atif Zafar1, Hemantkumar Deokar3, John K Buolamwini3, Jianhua Yang4, Jennifer H Foster4, Jia Zhou5, Ruiwen Zhang1,2. 1. Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, Houston, TX 77204, USA. 2. Drug Discovery Institute, University of Houston, Houston, TX 77204, USA. 3. Department of Pharmaceutical Sciences, College of Pharmacy, Rosalind Franklin University of Medicine and Science, North Chicago, IL 60064, USA. 4. Department of Pediatrics, Texas Children's Hospital, Baylor College of Medicine, Houston, TX 77030, USA. 5. Chemical Biology Program, Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, TX 77555, USA.
Abstract
BACKGROUND: Neuroblastoma is an aggressive pediatric solid tumor with an overall survival rate of <50% for patients with high-risk disease. The majority (>98%) of pathologically-diagnosed neuroblastomas have wild-type p53 with intact functional activity. However, the mouse double minute 2 (MDM2) homolog, an E3 ubiquitin ligase, is overexpressed in neuroblastoma and leads to inhibition of p53. MDM2 also exerts p53-independent oncogenic functions. Thus, MDM2 seems to be an attractive target for the reactivation of p53 and attenuation of oncogenic activity in neuroblastoma. METHODS: In this study, we evaluated the anticancer activities and underlying mechanisms of action of SP141, a first-in-class MDM2 inhibitor, in neuroblastoma cell lines with different p53 backgrounds. The findings were confirmed in mouse xenograft models of neuroblastoma. RESULTS: We demonstrate that SP141 reduces neuroblastoma cell viability, induces apoptosis, arrests cells at the G2/M phase, and prevents cell migration, independent of p53. In addition, in neuroblastoma xenograft models, SP141 inhibited MDM2 expression and suppressed tumor growth without any host toxicity at the effective dose. CONCLUSIONS: MDM2 inhibition by SP141 results in the inhibition of neuroblastoma growth and metastasis, regardless of the p53 status of the cells and tumors. These findings provide proof-of-concept that SP141 represents a novel treatment option for both p53 wild-type and p53 null neuroblastoma.
BACKGROUND:Neuroblastoma is an aggressive pediatric solid tumor with an overall survival rate of <50% for patients with high-risk disease. The majority (>98%) of pathologically-diagnosed neuroblastomas have wild-type p53 with intact functional activity. However, the mouse double minute 2 (MDM2) homolog, an E3 ubiquitin ligase, is overexpressed in neuroblastoma and leads to inhibition of p53. MDM2 also exerts p53-independent oncogenic functions. Thus, MDM2 seems to be an attractive target for the reactivation of p53 and attenuation of oncogenic activity in neuroblastoma. METHODS: In this study, we evaluated the anticancer activities and underlying mechanisms of action of SP141, a first-in-class MDM2 inhibitor, in neuroblastoma cell lines with different p53 backgrounds. The findings were confirmed in mouse xenograft models of neuroblastoma. RESULTS: We demonstrate that SP141 reduces neuroblastoma cell viability, induces apoptosis, arrests cells at the G2/M phase, and prevents cell migration, independent of p53. In addition, in neuroblastoma xenograft models, SP141 inhibited MDM2 expression and suppressed tumor growth without any host toxicity at the effective dose. CONCLUSIONS:MDM2 inhibition by SP141 results in the inhibition of neuroblastoma growth and metastasis, regardless of the p53 status of the cells and tumors. These findings provide proof-of-concept that SP141 represents a novel treatment option for both p53 wild-type and p53 null neuroblastoma.
Authors: Julie R Park; Susan G Kreissman; Wendy B London; Arlene Naranjo; Susan Lerner Cohn; Michael D Hogarty; Sheena C Tenney; Daphne Haas-Kogan; Peter John Shaw; Jacqueline M Kraveka; Stephen S Roberts; James Duncan Geiger; John J Doski; Stephan D Voss; John M Maris; Stephan A Grupp; Lisa Diller Journal: JAMA Date: 2019-08-27 Impact factor: 56.272
Authors: Katherine K Matthay; John M Maris; Gudrun Schleiermacher; Akira Nakagawara; Crystal L Mackall; Lisa Diller; William A Weiss Journal: Nat Rev Dis Primers Date: 2016-11-10 Impact factor: 52.329
Authors: Wei Wang; Elizabeth R Rayburn; Miao Hao; Yuqing Zhao; Donald L Hill; Ruiwen Zhang; Hui Wang Journal: Prostate Date: 2008-06-01 Impact factor: 4.104
Authors: Bieke Decaesteker; Kaat Durinck; Nadine Van Roy; Bram De Wilde; Christophe Van Neste; Stéphane Van Haver; Stephen Roberts; Katleen De Preter; Vanessa Vermeirssen; Frank Speleman Journal: J Pers Med Date: 2021-12-03